{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-25-004487","form_type":"8-K","ticker":null,"cik":"0001307624","company_name":"Healthtech Solutions, Inc./UT","filed_at":"2025-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.873482+00:00","generated_at":"2026-05-19T07:40:02.987754+00:00","sec_items":["1.01","2.01","5.02","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Healthtech sells patents ($5M) and World Reach units ($25M); CEO replaced","bullets":["Sold one patent and four applications to Papyrus Therapeutic for $5M cash; perpetual license back to HTWC for wound care products.","Sold 100% of World Reach Holdings to Papyrus Distribution for $25M base price, with $10M deferred via promissory notes.","CEO and director Jelena Olmstead resigned effective June 6, 2025; James Pesoli appointed CEO.","Transactions involved related parties (Pesoli and Olmstead had conflicting interests; approved by uninterested directors).","Patent license grants HTWC perpetual, worldwide, non-exclusive right to manufacture DermaBind products with monthly royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-25-004487","json":"https://secwatch.observer/filing/0001829126-25-004487.json","markdown":"https://secwatch.observer/filing/0001829126-25-004487.md","text":"https://secwatch.observer/filing/0001829126-25-004487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1307624/000182912625004487/0001829126-25-004487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1307624/000182912625004487/healthtech_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T07:40:02.987754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07c3c00784","claim":"James Pesoli was appointed as Chief Executive Officer at Healthtech Solutions, Inc./UT.","evidence_excerpt":"James Pesoli, the president and a director of the Company, was appointed as the chief executive officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1307624/000182912625004487/0001829126-25-004487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"3608cdfa7a","claim":"Jelena Olmstead resigned as Chief Executive Officer and Director at Healthtech Solutions, Inc./UT.","evidence_excerpt":"Jelena Olmstead, who served as chief executive officer and a director of the Company, resigned as a director, officer and employee of the Company and HTWC.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1307624/000182912625004487/0001829126-25-004487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer and Director"}],"fact_type":"executive_change"},{"claim_id":"a5d2edb2193694069ebc65328bed8e0269d4411c","claim":"Healthtech Solutions, Inc./UT completed a disposition involving Papyrus Distribution LLC for base purchase price equal to $25,000,000, subject to adjustment, with $10,000,000 deferred and payable via secured promissory notes (closed 2025-06-06).","evidence_excerpt":"the sellers sold to Papyrus Distribution 100% of the issued and outstanding equity interests of WR Holdings for a base purchase price equal to $25,000,000.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1307624/000182912625004487/0001829126-25-004487-index.htm","confidence":0.95,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Papyrus Distribution LLC"},{"label":"Consideration","value":"base purchase price equal to $25,000,000, subject to adjustment, with $10,000,000 deferred and payable via secured promissory notes"},{"label":"Closing","value":"2025-06-06"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}